Coherus Oncology (FRA:8C5) Net Interest Margin (Bank Only) %


FRA:8C5 Coherus Oncology Inc FRA:8C5
45 GF Score
Price €1.26
GF Value €0.67
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Coherus Oncology Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

FRA:8C5
45GF Score
Coherus Oncology Inc FRA:8C5
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Coherus Oncology (FRA:8C5) Overvalued in 2026?

Based on GuruFocus' analysis, Coherus Oncology stock appears to be overvalued. The current stock price of €1.26 is trading 87.3% above its estimated GF Value™ of €0.67. GuruFocus considers Coherus Oncology to be Significantly Overvalued.

Key valuation signals for FRA:8C5:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €0.67 vs. price of €1.26 (87.3% above fair value)
  • GF Score™: 45/100 with 6 warning signs

No single metric tells the full story. See the FRA:8C5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coherus Oncology Business Description

Other Exchanges CHRS:USA
Address 333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
45GF Score

Get the complete analysis for FRA:8C5

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.26
Price
€0.67
GF Value